Organovo develops dynamic, multicellular, 3D bioprinted human tissues that closely model native biology. With the NovoGen Brioprinter® Platform, the Company designs tissues for use in applications spanning preclinical safety testing, disease modeling, and therapeutics. ExVive™ Human Liver and Kidney Tissues are commercially available through their NovoView™ Preclinical Services and enable mechanistic insights into phenotypes that progress over time and require multiple cell types in a specific spatial organization, reflecting the true complexity of human biology.
Draper is an independent, not-for-profit corporation, which means its primary commitment is to the success of clients’ missions rather than to shareholders. For either government or private sector customers, Draper leverages its deep experience and innovative thinking to be an effective engineering research and development partner, designing solutions or objectively evaluating the ideas or products of others. Draper will partner with other organizations… Read More
KIYATEC prioritizes accurate ex vivo prediction of patients’ response to drug treatment, with a focus on data correlation to human clinical outcomes. We are experts at creating live phenotypic 3D cell-based models for drug response profiling, including complex co-cultures for immuno-oncology agents. We routinely create 3D screening assays using cancer cell lines, ex vivo 3D (EV3D) PDX tissues as well as primary tumor tissues (including patient-matched immune components) to accurately predict in vivo response. Learn more at www.kiyatec.com
Nortis is a biotech company that has developed tissue-engineering techniques and organ-on-a-chip systems for the creation of human micro tissue environment within small, disposable, microfluidic chips. Our technology enables living models of human organs that will drastically accelerate the discovery and introduction of new therapies and alleviate the use of lab animals. The Nortis technology is unique because it accurately replicates the biological structure and function of a living human organ… Read more.
SynVivo offers 3D cell-based models that enable real-time study of cell and drug interactions and accelerates discovery by providing a biologically realistic platform that more accurately depicts in vivo reality. Complex in vivo microvascular environment including scale, morphology, hemodynamics and cellular architecture are re-created in an in vitro format. SynVivo’s 3D models for blood brain barrier, tumor, inflammation and toxicology are morphologically and physiologically realistic and feature a side-by-side architecture enabling real-time visualization using standard analytical instrumentation. www.synvivobio.com
Our mission is to accelerate the discovery of new medicines with physiologically-relevant, structured human cells in high density plates. We develop and manufacture human induced pluripotent stem cell-derived cardiac and neuronal platforms for high throughput drug toxicity and efficacy screening. Predictive, accurate, and consistent, our human models enable scientists to economically conduct research in a simplified workflow… Read More
TARA Biosystems, Inc. provides predictive, in vitro human cardiac tissue models for use in drug discovery and safety assessment. TARA Biosystems offers a high fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The TARA solution will provide safety data earlier in the development cycle and a high fidelity discovery model.
ASLS is a global leader in bioprinting and tissue fabrication through enabling the complete workflow solution for designing, printing, assembling, and innovating 3D cellular and tissue models. ASLS offer a full-service business model including its patent pending BioAssemblyBot® Technology Platform, TSIM® Software, VIPM™, Professional Services and Supplies. ASLS is a subsidiary of 30-year old Advanced Solutions, Inc., with over 130 employees, 14 offices in the United States, and is headquartered in Louisville, Kentucky.
AxoSim’s Nerve-on-a-Chip technology predicts clinical results from the benchtop, helping pharmaceutical companies develop safer and more effective drugs. Employing micro-engineering techniques and novel biomaterials, AxoSim has developed a 3D iPSC-based model which mimics living tissue in both form and function, enabling in vivo metrics from an in vitro platform. The Nerve-on-a-Chip platform delivers high-content data as a more accurate, less expensive, and faster alternative to animal testing.
Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development & discovery. Our phenotypic CANscript platform delivers powerful insight for our biopharma partners. Because CANscript conserves the native tumor microenvironment and delivers 1:1 clinical correlation, it can be used to predict response of an indication to a specific drug (or drug combination), or to better understand MOA of a given compound.